Abstract:Background: Assess the current and potential indications of photobiomodulation (PBM) therapy and their level of evidence in the prevention or treatment of side effects related to oncology treatments (radiation therapy, and to a minimal extent favored and hematopoietic stem cell transplants). And report on the recommended modalities (parameters and doses) of PBM therapy. Materials and methods: The Embase, Medline/PubMed, Cochrane, EBSCO, Scopus, and LILACS databases were systematically reviewed to include and analyze publications of clinical studies that evaluated PBM in the prevention or management side effects related to cancer treatments. The keywords used were "photobiomodulation"; "low level laser therapy"; "acute oral mucositis"; "acute dysphagia"; "acute radiation dermatitis"; "lymphedema"; "xerostomia"; "dysgeusia"; "hyposalivation"; "lockjaw"; "bone necrosis"; "osteoradionecrosis"; "radiation induced fibrosis"; "voice and speech alterations"; "palmar-plantar erythrodysesthesia"; "graft versus host disease"; "peripheral neuropathy"; "chemotherapy induced alopecia". Prospective studies were included, while retrospective cohorts and non-original articles were excluded from the analysis. Results: PBM in the red or infrared spectrum has been shown to be effective in randomized controlled trials in the prevention and management of certain complications related to radiotherapy, in particular acute mucositis, epitheliitis and upper limb lymphedema. The level of evidence associated with PBM was heterogeneous, but overall remained moderate. The main limitations were the diversity and the lack of precision of the treatment protocols which could compromise the efficiency and the reproducibility of the results of the PBM. For other effects related to chemo/radiation therapy (dysgeusia, osteonecrosis, peripheral neuropathy, alopecia, palmar-plantar erythrodysaesthesia) and haematopoietic stem cell transplantation (graft versus host disease), treatment with PBM suffers from a lack of studies or limited studies at the origin of a weakened level of proof. However, based on these results, it was possible to establish safe practice parameters and doses of PBM. Conclusion: Published data suggest that PBM could therefore be considered as supportive care in its own right for patients treated with radiation, chemotherapy, immunotherapy, hormone therapy or targeted therapies, whether in clinical practice or clinical trials. therapies. However, until solid data have been published on its long-term safety, the use of PBM should be considered with caution and within the recommended parameters and doses, particularly when practiced in areas of known or possible tumours. In this case, the patient should be informed of the theoretical benefits and risks of PBM in order to obtain informed consent before treatment.

The review of the light parameters and mechanisms of Photobiomodulation on melanoma cells

Enhancement of Photodynamic Cancer Therapy by Physical and Chemical Factors

Considerations for the Use of Photobiomodulation in the Treatment of Retinal Diseases

Irradiance Plays a Significant Role in Photobiomodulation of B16F10 Melanoma Cells by Increasing Reactive Oxygen Species and Inhibiting Mitochondrial Function.

Comparative Transcriptome Analysis of Gene Expression Patterns on B16F10 Melanoma Cells under Photobiomodulation of Different Light Modes.

Wavelength-dependent photobiomodulation (PBM) for proliferation and angiogenesis of melanoma tumor in vitro and in vivo

Reviewing the efficiency of photobiomodulation therapy in oncological treatment

The pulse light mode enhances the effect of photobiomodulation on B16F10 melanoma cells through autophagy pathway

Photobiomodulation for melasma treatment: Integrative review and state of the art

Experimental study on the safety of photobiologic regulation therapy in the treatment of some non-epidermal tumors

Photobiomodulation CME Part II: Clinical Applications in Dermatology

Photobiomodulation CME Part I: Overview and Mechanism of Action

Photobiomodulation in Ophthalmology: A Comprehensive Review of Bench-to-Bedside Research and Clinical Integration

Mechanisms of PhotoBioModulation (PBM) focused on oral mucositis prevention and treatment: a scoping review

Low-Intensity Visible and Near-Infrared Light-Induced Cell Signaling Pathways in the Skin: A Comprehensive Review

[Photobiomodulation in the prevention and the management of side effects of cancer treatments: Bases, results and perspectives]

808-nm Photobiomodulation Affects the Viability of a Head and Neck Squamous Carcinoma Cellular Model, Acting on Energy Metabolism and Oxidative Stress Production

Effect of 460 nm blue light PBM on human MeWo melanoma cells

Brain photobiomodulation therapy on neurological and psychological diseases

Photobiomodulation use in ophthalmology - an overview of translational research from bench to bedside

Photobiomodulation Improves Anti-Tumor Efficacy of Photodynamic Therapy against Resistant MCF-7 Cancer Cells